Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma
Janssen said late-stage combination trials for its immunotherapy daratumumab increased progression-free survival for patients with multiple myeloma.
The company said the Phase III study for the drug in combination with lenalidomide (an immunomodulatory agent) and dexamethasone (a corticosteroid) reduced the risk of disease progression or death by 63%.
Professor Gordon Cook, chief investigator for the study, said: “Daratumumab, the first drug of its kind, represents a significant advance in the field of multiple myeloma care. Building on successful monotherapy studies, this work shows daratumumab can be used in combination with other drugs to effectively control the disease and improve survival.”
The study was conducted with 569 patients.
Rozlyn Bekker, medical director UK and Ireland Janssen, said: “We are delighted with the results of the MMY3003 trial as it’s the second Phase III study with daratumumab in combination to standard therapy to meet its primary endpoint before the final analysis.”
Daratumumab received marketing authorisation in the UK (and across the EU) in May 2016 to treat multiple myeloma.
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 …
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …